Experienced in Menopause

Dr. Madhukar H. Trivedi

Psychiatry
5323 Harry Hines Blvd, 
Dallas, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Menopause
5323 Harry Hines Blvd, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Madhukar Trivedi is a Psychiatrist in Dallas, Texas. Dr. Trivedi is rated as an Experienced provider by MediFind in the treatment of Menopause. His top areas of expertise are Major Depression, Bipolar Disorder (BPD), Post-Traumatic Stress Disorder (PTSD), and Opioid Use Disorder. Dr. Trivedi is currently accepting new patients.

His clinical research consists of co-authoring 486 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Menopause.

Specialties
Psychiatry
Licenses
Psychiatry & Neurology in TX
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

5323 Harry Hines Blvd, Dallas, TX 75390

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Resilience in Adolescent Development
Resilience in Adolescent Development
Enrollment Status: Recruiting
Publish Date: May 06, 2025
Characterizing Inflammatory Profiles and Suicidal Behavior in Adolescents
Characterizing Inflammatory Profiles and Suicidal Behavior in Adolescents
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2025
Intervention Type: Other
Emergency Department-Initiated Buprenorphine Validation Network Trial
Emergency Department-Initiated Buprenorphine Validation Network Trial
Enrollment Status: Completed
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drugs: CAM2038, Buprenorphine
Study Phase: Phase 2
Innovative Development of Research Engagement Manual (I-DREM): Strategies to Enhance Recruitment and Retention of African American/Black Individuals in Clinical Trials
Innovative Development of Research Engagement Manual (I-DREM): Strategies to Enhance Recruitment and Retention of African American/Black Individuals in Clinical Trials
Enrollment Status: Completed
Publish Date: August 13, 2024
NIDA CTN Protocol 0090 Innovatively Increasing PCP Prescribing of Buprenorphine: Measurement Based Care and Integrated Electronic Solution (MBC4OUD)
NIDA CTN Protocol 0090 Innovatively Increasing PCP Prescribing of Buprenorphine: Measurement Based Care and Integrated Electronic Solution (MBC4OUD)
Enrollment Status: Completed
Publish Date: June 18, 2024
Intervention Type: Other
A Phase 3, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant
A Phase 3, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant
Enrollment Status: Terminated
Publish Date: June 14, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo Controlled Exploratory Efficacy and Safety Study of SPD489 in Adults 18-55 Years With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant
A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo Controlled Exploratory Efficacy and Safety Study of SPD489 in Adults 18-55 Years With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant
Enrollment Status: Completed
Publish Date: June 14, 2021
Intervention Type: Drug
Study Phase: Phase 2
The SPD489-323 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant
The SPD489-323 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant
Enrollment Status: Completed
Publish Date: June 09, 2021
Intervention Type: Drug
Study Phase: Phase 3
The SPD489-322 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant
The SPD489-322 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant
Enrollment Status: Completed
Publish Date: June 09, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Multicenter, Double- Blind, Parallel-group, Randomized, Placebo-controlled, Forced-dose Titration, Dose-ranging Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant
A Phase 2, Multicenter, Double- Blind, Parallel-group, Randomized, Placebo-controlled, Forced-dose Titration, Dose-ranging Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant
Enrollment Status: Completed
Publish Date: June 09, 2021
Intervention Type: Drug
Study Phase: Phase 2
Promoting Activity in Cancer Survivors
Promoting Activity in Cancer Survivors
Enrollment Status: Completed
Publish Date: January 26, 2021
Intervention Type: Behavioral
Study Phase: Not Applicable
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)
Enrollment Status: Completed
Publish Date: June 19, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

486 Total Publications

Feasibility and Acceptability of a Brief Intervention for Youth Suicidal Thoughts and Behaviors Among Pediatric Primary Care Providers.
Feasibility and Acceptability of a Brief Intervention for Youth Suicidal Thoughts and Behaviors Among Pediatric Primary Care Providers.
Journal: Evidence-based practice in child and adolescent mental health
Published: August 25, 2025
Similar Doctors
Experienced in Menopause
Dr. Madeline Andrew
Psychiatry
Experienced in Menopause
Dr. Madeline Andrew
Psychiatry
511 E John Carpenter Fwy Ste 500, 
Irving, TX 
 (7.3 miles away)
214-265-6565
Languages Spoken:
English, Bengali, Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Madeline Andrew is a Psychiatrist in Irving, Texas. Dr. Andrew is rated as an Experienced provider by MediFind in the treatment of Menopause. Her top areas of expertise are Generalized Anxiety Disorder (GAD), Seasonal Affective Disorder (SAD), Major Depression, and Menopause. Dr. Andrew is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Trivedi's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile